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Abstract: The expression of proliferating cell nuclear antigen (PCNA) correlates to cell proliferation and for this reason it is
commonly considered as one of proliferation markers. Since proliferation rate is an important factor determining the tumor
aggressiveness, the evaluation of PCNA index (the percentage of PCNA-immunopositive nuclei in the investigated tumor
sample) is suggested as useful in predicting pituitary adenoma outcome. Seventy three unselected, surgically removed pituitary
adenomas were immunostained with antibodies against the pituitary hormones or their subunits and against the proliferating
cell nuclear antigen (PCNA).The highest PCNA index was found in ACTH-immunopositive tumors without the manifestation
of the Cushing’s disease ("silent" corticotropinomas). This value was significantly different in comparison to other adenoma
subtypes including corticotropinomas manifesting themselves by Cushing’s disease. The lowest PCNA index was noticed in
monohormonal GH-secreting tumors. The adenomas which express more than one hormone (plurihormonal adenomas) seem
to have a higher PCNA indices than monohormonal ones; the difference was significant in the case of mono- and plurihormonal
prolactinomas. The recurrent tumors presented a higher mean PCNA index as compared to the primary tumors, although the
difference was significant only in the case of prolactinomas. These findings suggest that the proliferative potential of pituitary
adenomas is related to the tumor recurrence and hormone expression. (www.cm-uj.krakow.pl/FHC)
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Introduction
Proliferating cell nuclear antigen (PCNA) is a nuclear
auxilliary protein of deoxyribonucleic acid polymer-
ase delta. Its expression correlates to cell proliferation
and for this reason it is commonly considered as one
of proliferation markers. Since proliferation rate is an
important factor determining the tumor aggressive-
ness, the evaluation of PCNA index (the percentage
of PCNA-immunopositive nuclei in the investigated
tumor sample) is suggested as useful in predicting the
pituitary adenoma outcome. Hsu et al. [6] showed that
PCNA index was higher in pituitary adenomas that
would recurr, than in nonrecurrent tumors. This obser-
vation was confirmed in further studies [2, 16]. PCNA
indices were also found to be higher in invasive vs
non-invasive pituitary adenomas [1, 14, 19]. PCNA
expression in pituitary adenomas correlates also with
another proliferation marker, nucleolar organizing re-
gions (NOR) [10]. However, other authors did not find
the correlation between PCNA expression and pituitary
tumor recurrence and/or invasiveness [5, 7, 9, 17]. The
data concerning the proliferative activity of different
types of pituitary adenomas are not univocal. Otsuka
et al. [15] did not show differences in PCNA express-
ion between GH-producing, PRL-producing, FSH-
producing and nonfunctioning adenomas. On the
other hand, the higher proliferation rate was reported
in the adrenocorticotrophic tumors in comparison to
other types of pituitary adenomas [12]. Our earlier
studies showed that adenomas expressing gonadotro-
pins or free alpha subunit (gonadotropinomas/alpho-
mas) and alpha-subunit co-expressing tumors had
higher PCNA indices vs alpha-SU-immunonegative
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adenomas [10]. The aim of the present study was to
answer the following questions: (1) Does PCNA ex-
pression vary between non-recurrent and recurrent
adenomas? (2) Does PCNA expression depend on the
endocrine phenotype of pituitary adenoma? 
Materials and methods 
Seventy three unselected, surgically removed pituitary adenomas
were studied. The tumors were fixed in Bouin-Hollande fixative and
embedded in paraffin wax. Five μm sections were immunostained
with antisera against the pituitary hormones and alpha-subunit
(alpha-SU). The following antisera were used: polyclonal anti-
human PRL (Dako, Denmark, prediluted by the manufacturer),
polyclonal anti-human GH (Immunon, USA, prediluted by the
manufacturer), monoclonal anti-human LH (Dako, prediluted by the
manufacturer), monoclonal anti-human FSH (Dako, working dilu-
tion 1:50), monoclonal anti-human TSH (Immunotech, France,
working dilution 1:100), monoclonal anti-alpha SU (Immunotech,
working dilution 1:100), polyclonal anti-ACTH (Sigma, USA,
DAKO or Immunon, working dilution 1:100). The sections were
incubated with the primary antibodies for 24 hours at 4˚C. The
primary antibodies were then detected using the appropriate biotiny-
lated secondary antibodies. The immunoreaction was visualized by
the streptavidin-peroxidase complex (StreptABC/HRP, Dako) and
3,3’-diaminobenzidine. PCNA expression was assessed using the
anti-PCNA monoclonal antibody (DAKO, prediluted by the manu-
facturer) and EnVision System AP (Dako). The number of PCNA-
positive nuclei was estimated in 1000 randomly scored cells of each
tumor and expressed in percent as PCNA index.
The numerical data were analyzed statistically by means of
ANOVA and Mann-Whitney tests.
Results 
Twenty four adenomas were found to express FSH
and/or LH or free alpha SU and were diagnosed as
gonadotropinomas. Fourteen tumors were diagnosed as
prolactinomas, 11 expressed both GH and PRL (soma-
to-prolactinomas), 5 expressed solely GH (somatotropi-
nomas). Fourteen tumors expressed ACTH. One of them
was an adenoma removed from a patient suffering from
Cushing’s disease submitted prior to bilateral adrenalec-
tomy (Nelson’s syndrome), 9 were removed from pa-
tients with Cushing’s disease and the other 4 were found
in patients without any symptoms of hypercortisolism
(silent corticotropinomas). The remaining 4 adenomas
were immunonegative for all the investigated pituitary
peptides (null cell adenomas). 
The relations between PCNA index and the express-
ion of pituitary hormones in the tumor are shown in
Figure 1. The highest PCNA index was found in
ACTH-immunopositive tumors without the manifesta-
tion of the Cushing’s disease (silent corticotropinomas
- 6.47±2.74%; Figs. 2 and 3). This value is significantly
different in comparison to other adenoma subtypes in-
cluding corticotropinomas manifesting themselves by
Cushing’s disease (2.4±1.1%). The lowest PCNA index
was noticed in monohormonal GH-secreting tumors
(0.94±0.22%). It seems that the adenomas immunone-
gative for all the investigated pituitary hormones (null
cell adenomas) have in the majority low PCNA express-
ion. This study included 4 such adenomas. All but one
had low PCNA index (<1%) and the remaining unexpec-
tedly had it very high (13.7%). Because of this heteroge-
neity we did not calculate the mean value for this
adenoma subtype and we did not consider it in statistical
evaluation. The adenomas which expressed more than
one hormone (plurihormonal adenomas) seemed to have
higher PCNA indices than monohormonal ones; the
difference was significant in the case of mono- and
plurihormonal prolactinomas (1.3±0.5% vs 3.1±0.7%,
respectively). Moreover, in prolactinomas and gonado-
tropinomas, a tendency towards higher PCNA indices in
men than in women was observed (Fig. 4). However, the
difference was not statistically significant. The recurrent
tumors presented a higher mean PCNA index
(3.2±0.6%) as compared to the primary tumors
(2.5±0.4%), but the difference was again statistically
insignificant, except recurrent vs primary prolactinomas
(3.15±1.15% vs 1.47±0.38%, p<0.05, see Fig. 5).
Discussion
The data presented above indicate that the proliferative
potential of pituitary adenomas, estimated as PCNA
expression, is, at least in part, related to the endocrine
phenotype of adenoma. The most interesting observa-
tion concerns the high PCNA expression in ACTH-im-
munopositive tumors without clinically and/or
biochemically manifested hypercortisolism ("silent"
corticotropinomas). It is well known that ACTH-secret-
ing adenomas become very aggressive in patients suf-
fering from Cushing’s disease after bilateral
adrenalectomy (so-called Nelson’s syndrome [8, 11,
13]. It is assumed that the fast growth of these tumors
depends on the lack of feedback inhibition by cortisol.
Fig. 1. PCNA indices (means±SEM) of pituitary adenomas in rela-
tion to endocrine phenotype. Asterisk indicates the statistically sig-
nificant difference (p<0.05) vs the remaining types of adenomas.
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Nowadays the Nelson’s syndrome becomes rare be-
cause the bilateral adrenalectomy is not recommended
for the treatment of Cushing’s disease. In our material
we have only one case of ACTH-immunopositive tumor
from patient with Nelson’s syndrome. This tumor
presented a high PCNA index comparable with those
found in "silent" corticotropinomas (6.1%). It seems to
us that in the case of "silent" corticotropinomas the
situation may be close to that observed in Nelson’s
syndrome. "Silent" corticotropinomas express ACTH or
ACTH-like peptide(s) but do not secrete biologically
active ACTH. In the majority of cases included in this
study, not only was hypercortsolism absent but the func-
tion of the adrenal cortex was impaired. It means that the
growth of tumoral corticotrophs was not restrained by
the endogenous cortisol like in Nelson’s syndrome. 
Fig. 3. PCNA-immunopositive nuclei
(deep purple) in the same tumor as in
Figure 1. × 400.
Fig. 2. ACTH immunostaining in "clini-
cally non-functioning" adenoma from
62-year old man. × 400.
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The relatively high PCNA indices were also ob-
served in gonadotropinomas. This observation is in
agreement with our earlier findings [10,16]. These tu-
mors are assumed to grow slowly but they are diagnosed
usually in the late stage as the giant macroadenomas.
They exhibit also a high recurrence rate after surgical
treatment. 
Another observation worth to be underlined is higher
PCNA expression in plurihormonal vs monohormopnal
prolactinomas. The plurihormonal prolactinomas in our
material co-expressed, in addition to PRL, the following
pituitary hormones: free alpha-SU (2 cases), ACTH (2
cases), GH (2 cases), FSH (1 case) and TSH (1 case). A
slight difference in PCNA indices between mixed
GH/PRL and "pure" GH-secreting adenomas in acro-
megalic patients in favor of the former should also be
noticed. It is worth to recall that Desai et al. [4] have
found that co-expression of glycoprotein hormones or
free alpha-subunit by ACTH-secreting adenomas is as-
sociated with their enhanced aggressiveness. In our ma-
terial, the recurrence rate of plurihormonal adenomas is
twice as high as in the monohormonal ones, when we
exclude the gonadotropin-expressing tumors which
have very high recurrence rate (unpublished observa-
tions). The question whether plurihormonality of pitui-
tary adenomas can be a predictive factor of aggres-
siveness needs further studies.
Last but not least, the patient’s gender can also in-
fluence the proliferation potential and aggressiveness of
the pituitary adenoma. Such an observation concerning
prolactinomas was reported by French authors [3,18].
Our findings confirm it and suggest that the same may
also concern another phenotype of adenomas, namely
gonadotropinomas. The relationship between the recur-
rence and proliferative potential of pituitary adenomas
is a matter of controversy (see papers cited in Introduc-
tion). Nevertheless, the data presented in the present
study taken together with earlier observations from our
and some other laboratories [1, 2, 6, 14, 16, 19] strongly
suggest such a relationship.
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